A Study of Bexarotene Combined With Radiotherapy in People With Mycosis Fungoides

The researchers are doing this study to test the safety of combining bexarotene with TSEB radiotherapy in people who have a common form of CTCL called mycosis fungoides (MF). Bexarotene is a form of vitamin A that activates proteins called retinoid X receptors, which may stop the growth of cancer cells and kill them. TSEB radiotherapy is a type of radiation therapy that treats the entire surface of the skin with very low doses of radiation to kill cancer cells and shrink tumors. This type of radiation does not pass through the outer layers of the skin into the tissues and organs below the ski

Trial Details

NCT ID
NCT05296304
Phase
PHASE1
Sponsor
Memorial Sloan Kettering Cancer Center
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Bexarotene
  • Total Skin Electron Beam (TSEB)
Locations (sample)
  • Commack, New York, United States|40.84288,-73.29289
  • New York, New York, United States|40.71427,-74.00597
  • Rockville Centre, New York, United States|40.65871,-73.64124

Key Eligibility Criteria

  • Age ≥18 years
  • Pathologically confirmed cutaneous T-cell lymphoma consistent with mycosis fungoides (MF) based on biopsy done or reviewed at MSKCC
  • Stage IB or higher MF per ISCL/EORTC criteria; concurrent diagnosis of Sézary syndrome permissible. Patients who have not had prior systemic therap…
  • Baseline mSWAT score of at least 10

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →